David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Image of David B. Agus, MD
Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

  • American Cancer Society: Physician Research Award, 1996
     – 2001
  • Sloan-Kettering Institute: Clinical Scholar Award, 1996
  • American Cancer Society: Clinical Oncology Fellowship Award, 1994
  • HealthNetwork Foundation: Excellence Award, 2008
  • Geoffrey Beene Foundation: Rock Stars of Science™, 2009
  • Biotech Humanitarian Award: Selected Judge, 2009
  • USC Association of Trojan Leagues: Outstanding Service Award, 2013
  • American College of Physicians: Fellow, 2016
  • Ellis Island Medal of Honor: Medalist, 2017

Research Funding

  • (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
  • UCLA SPORE in Prostate Cancer
    NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Publications

  • Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15.. View in PubMed
  • Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61.. View in PubMed
  • Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81.. View in PubMed
  • Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79.. View in PubMed
  • Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80.. View in PubMed
  • Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090.. View in PubMed
  • Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55.. View in PubMed
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57.. View in PubMed
  • Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10.. View in PubMed
  • Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5.. View in PubMed